| Name | Title | Contact Details |
|---|
Cedars-Sinai is a non-profit, academic, community-centric, Level 1 Trauma Center in Los Angeles, California. Recognized internationally, Cedars-Sinai brings together top healthcare professionals collaborating to provide exceptional patient care. A combination of patient satisfaction scores, clinical performance initiatives, excellent medical outcomes, national designations and awards and ongoing research and academic programs have earned Cedars-Sinai a top spot on the Honor Roll in the 2014-15 issue of America`s Best Hospitals by U.S. News and World Report. Out of nearly 5,000 hospitals surveyed for the annual rankings, Cedars-Sinai is among just 17 hospitals nationwide to earn the magazine’s Honor Roll designation. To be named to the Honor Roll, a hospital must be rated among the nation’s top 50 programs in at least six specialties. Cedars-Sinai was ranked in 12 categories, including: Cancer; Cardiology and Heart Surgery; Diabetes and Endocrinology; Ear, Nose and Throat; Gastroenterology and GI Surgery; Geriatrics; Gynecology; Nephrology, Neurology and Neurosurgery; Orthopedics; Pulmonology; and Urology. Cedars-Sinai has also received its fourth consecutive Magnet® recognition for nursing excellence from the American Nurses Credentialing Center (ANCC), becoming the hospital with the longest-running Magnet designation in California. Nationwide, only about 5% of hospitals have earned the four-year Magnet designation. Cedars-Sinai was the first Southern California hospital to earn the Magnet honor in 2000, and one of only six hospitals to receive this designation three times. Studies show that Magnet hospitals tend to have lower mortality and infection rates, as well as higher patient satisfaction and nurse staffing levels.
Continucare Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Continucare Corporation is based in Miami, FL. You can find more information on Continucare Corporation at www.continucare.com
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Seaside Healthcare, our mission is to improve the lives of our patients and their communities through outcome-based, cost-effective mental-health services delivered with dignity and respect.
Rovin Med, is a Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.